Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update

Zhang, Wenhao; Zhang, Xinhua

doi:10.4103/1008-682x.167721

Cited by 12 publications

(10 citation statements)

References 137 publications

(156 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PDE5 inhibitors are the most widely prescribed medicine for patients with ED. Currently available PDE5 inhibitors are sildenafil (Viagra; Pfizer, New York City, NY, USA), vardenafil (Levitra, Staxyn), tadalafil (Cialis; Eli Lilly), avanafil (Stendra; VIVUS Inc., Campbell, CA, USA), udenafil (Zydena; Dong-A PharmTech, Seoul, Korea), and mirodenafil (Mvix; SK Chemical, Seongnam, Korea) [58].…”

Section: Erectile Dysfunctionmentioning

confidence: 99%

Obesity and Erectile Dysfunction: From Bench to Clinical Implication

Moon

Park

Kim

2019

World J Mens Health

View full text Add to dashboard Cite

Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both conditions may share an internal pathologic environment, also known as common soil. Their main pathophysiologic processes are oxidative stress, inflammation, and resultant insulin and leptin resistance. Moreover, the severity of ED is correlated with comorbid medical conditions, including obesity. Therefore, amelioration of these comorbidities may increase the efficacy of ED treatment with phosphodiesterase 5 inhibitors, the first-line medication for patients with ED. Although metformin was originally developed as an insulin sensitizer six decades ago, it has also been shown to improve leptin resistance. In addition, metformin has been reported to reduce oxidative stress, inflammatory response, and body weight, as well as improve ED, in animal and human studies. Moreover, administration of a combination of metformin and phosphodiesterase 5 inhibitors improves erectile function in patients with ED who have a poor response to sildenafil and are insulin resistant. Thus, concomitant treatment of metabolic derangements associated with obesity in patients with ED who are obese would improve the efficacy and reduce the refractory response to penile vasodilators. In this review, we discuss the connecting factors between obesity and ED and the possible combined treatment modalities.

show abstract

Section: Erectile Dysfunctionmentioning

confidence: 99%

Obesity and Erectile Dysfunction: From Bench to Clinical Implication

Moon

Park

Kim

2019

World J Mens Health

View full text Add to dashboard Cite

show abstract

“…Zaprinast activates the G-protein coupled receptor, GPR35, that plays a crucial role in cardiovascular disease, pain, regulation of inflammation, hypertension, diabetes, and irritable bowel disease [117,118]. The main characteristics of PDE5Is are summarized in Table 7 [34,112,113,[119][120][121][122][123][124][125]. PDE5Is interfere selectively with cGMP hydrolysis by PDE5, increasing intracellular cGMP, which results in smooth muscle relaxation/raised arterial blood flow improving penile erection.…”

Section: Discussionmentioning

confidence: 99%

Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review

Georgiadis

Zisis

Docea

et al. 2020

JCM

View full text Add to dashboard Cite

Acute kidney injury (AKI) is associated with increased morbidity, prolonged hospitalization, and mortality, especially in high risk patients. Phosphodiesterase 5 inhibitors (PDE5Is), currently available as first-line therapy of erectile dysfunction in humans, have shown a beneficial potential of reno-protection through various reno-protective mechanisms. The aim of this work is to provide a comprehensive overview of the available literature on the reno-protective properties of PDE5Is in the various forms of AKI. Medline was systematically searched from 1946 to November 2019 to detect all relevant animal and human studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. In total, 83 studies were included for qualitative synthesis. Sildenafil is the most widely investigated compound (42 studies), followed by tadalafil (20 studies), icariin (10 studies), vardenafil (7 studies), zaprinast (4 studies), and udenafil (2 studies). Even though data are limited, especially in humans with inconclusive or negative results of only two clinically relevant studies available at present, the results of animal studies are promising. The reno-protective action of PDE5Is was evident in the vast majority of studies, independently of the AKI type and the agent applied. PDE5Is appear to improve the renal functional/histopathological alternations of AKI through various mechanisms, mainly by affecting regional hemodynamics, cell expression, and mitochondrial response to oxidative stress and inflammation.

show abstract

“…To date, eleven different PDE families have been identified, each typically having several different isoforms and splice variants. Among these, PDE5 is specific for cGMP and PDE5i have been proved to be of pharmacological relevance, widely studied and used (24). PDE5i were originally designed to treat cardiovascular diseases and later used for the treatment of male erectile dysfunction with acceptable results (4).…”

Section: Mechanism Of Action Of Phosphodiesterase Type 5 Inhibitorsmentioning

confidence: 99%

“…A few studies analysed the efficacy of sildenafil as a treatment for many subtypes of FSD (26) but even less is known about the role of other molecules belonging to the PDE5i family. Newly developed compounds may contain certain advantages over sildenafil, such as higher selectivity for PDE5 compared with other isoenzymes, faster onset, longer duration of effect and absence of food effect on absorption, which consequently, allowing more flexibility in sexual activity (24).…”

Section: Mechanism Of Action Of Phosphodiesterase Type 5 Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women

Borghi

Dell’Atti²

2017

Arch Ital Urol Androl

View full text Add to dashboard Cite

Female Sexual Disorders (FSD) include a complex, multidimensional, individual experience that can change as an individual age, suggesting that these problems are caused by multiple factors including psychosocial factors, personal relationships, pathologic changes caused by diseases, and pharmacologic influences. Menopause is an important time for middle aged women and postmenopausal physiological changes could have a significant role in the development of FSD. Few is still known about their correct definition and treatment. Their incidence, prevalence and risk factors are difficult to define because of a high level of overlap in the experience of problems with desire, arousal, and orgasm. Little evidences are known about the best therapeutic approach, and both non-pharmacological and pharmacological treatment options have been described. Among these, phosphodiesterase type 5 inhibitors could be an effective option for many subtypes of female sexual disorders, with an improvement in different aspects of sexual function, such as desire, arousal, orgasm and sexual satisfaction. In this paper authors reviewed what is already known about the use of these vasoactive agents, particularly tadalafil, as a treatment option for female sexual disturbances.KEY WORDS: Female Sexual Disorders; Phosphodiesterase type 5 inhibitors; Tadalafil; Women. changes could have a significant role in the development of FSD. Nevertheless, despite an increased awareness of its pathophysiology, studies didn't find an agreement on what is the best therapeutic approach and currently there are no drugs approved for most of the complaints (3). Phosphodiesterase type 5 inhibitors (PDE5i) have been widely used for the treatment of male sexual dysfunction (4). In this paper authors review the current literature on FSD and analyse PDE5i, particularly tadalafil, as a treatment option for this health issue. CURRENT KNOWLEDGE OF FEMALE SEXUAL DYSFUNCTIONThe concept of FSD comprises a wide range of disorders, whose definition has undergone numerous changes and classifications in the past. Different definitions included hypoactive sexual desire, impaired subjective or physical genital arousal, sexual pain and inability to achieve orgasm, which are multidimensional issues, often coexisting. The most frequently used classification systems are the International Classification of Diseases, 10 th Edition (ICD-10) by the WHO (5) and the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-5) by the American Psychiatric Association (6). The former subdivides the disorders as organic or non organic. For female, organic disorders include vaginismus and dyspareunia of organic aetiology. Non organic female sexual dysfunctions include lack of sexual desire, sexual aversion or lack of sexual enjoyment, failure of genital response, orgasmic dysfunction, non-organic vaginismus, non-organic dyspareunia, excessive sexual drive and two non-specific codes. These causes are summarized in Table 1. The latter, introduced in 2013, defines the most prevalent ...

show abstract

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update

Cited by 12 publications

References 137 publications

Obesity and Erectile Dysfunction: From Bench to Clinical Implication

Obesity and Erectile Dysfunction: From Bench to Clinical Implication

Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review

Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women

Contact Info

Product

Resources

About